3Isomaa B, Almgren P, Tuomi T, et al. Cardiovasular morbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care, 2001,24 : 683 - 689.
4Yoshimoto T, Naruse M, Shizume H, et al. Vasculoprotective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy[J]. Atherosclerosis, 1999,145 : 333 - 340.
5Martens FM, Vissern FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones[J]. Drugs, 2002, 62 :1463 - 1480.
6Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type Ⅱ diabetes[J]. Diabetes, 1996,45: 1661 - 1669.
8Mesejo A,Acosta JA,Ortega C,et al.Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patients.Clin Nutr,2003,22:295-305.
9Shang E,Griger N,Sturm JW,et al.Pump-assisted enteral nutrition can prevent aspiration in bed-ridden percutaneous endoscopic gastrostomy patients.JPEN,2004,28:180-183.
10Shang E,Griger N,Sturm JW,et al.Pump-assisted versus gravity-controlled enteral nutrition in long-term percutaneous endoscopic gastrostomy patients:a prospective controlled trial.JPEN,2003,27:216-219.
